A fresh player in the gene-editing arena has emerged, raising a substantial $230 million in funding. This financial backing positions the startup to advance its innovative projects.
In addition to the funding, the startup has negotiated contracts with a Chinese company, which could enhance its operational capabilities and market reach in Asia.
Furthermore, the company executed a reverse-merger with an existing biotech firm, a move that may streamline its path to growth and development in the competitive biotech landscape.